Drug intelligence / Profile preview

CS-002

Development stage: Phase 2
Lead developer: Jupiter Wellness
Modality: Small Molecules
Administration: Topical

Overview

CS-002 is a small molecule **mTOR (mammalian target of rapamycin) inhibitor** being developed as a topical treatment for canities (grey hair). Preclinical in vitro and pilot clinical studies have demonstrated its ability to re-pigment grey hair, presumably by modulating melanocyte biology via mTOR pathway inhibition. The compound is under investigation in a phase 2 clinical trial for this indication, with the goal of determining its safety and efficacy for grey hair reversal.

Targets

mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on CS-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS-002.

Explore the full profile